您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Cetrelimab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cetrelimab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:2050478-92-5
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品名称
JNJ 63723283
JNJ 3283
产品介绍
Cetrelimab (JNJ 63723283; JNJ 3283) 是一种靶向PD-1的人源化 IgG4κ 单克隆抗体。Cetrelimab 结合PD-1的 Kd为 1.72 nM (HEK293 细胞)。由此,Cetrelimab 阻断PD-1PD-L1PD-L2的相互作用 (IC50分别为 111.7 ng/mL 和 138.6 ng/mL)。Cetrelimab 还刺激外周 T 细胞,增加细胞因子 (IFN-γ,IL-2,TNF-α) 水平,并抑制体内肿瘤生长。
生物活性

Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ mAb targetingPD-1. Cetrelimab bindsPD-1(Kd=1.72 nM, HEK293) to block the interaction ofPD-1withPD-L1andPD-L2(IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increasesIFN-γ,IL-2,TNF-αlevel and inhibits tumor growth in vivo[1].

IC50& Target

PD-1/PD-L1, PD-1/PD-L2, IFN-γ, IL-2, and TNF-α[1]

体外研究
(In Vitro)

Cetrelimab (0.01-30 nM; 5 d) binds to endogenous PD-1 on activated CD4+and CD8+T cells with EC50s of 0.16-0.22 μg/mL and 0.17-0.22 μg/mL, respectively[1].
Cetrelimab (0.01-30 μg/mL; 24 h) reverse PD-1-mediated suppression of TCR signaling in Jurkat-PD-1 NFAT reporter cells with CHO-K1 expressing PD-L1[1].
Cetrelimab (0.001-100 nM; 6 d) increases IFN-γ, IL-2, and TNF-α with EC50s of 0.08 ng/mL, 0.07 ng/mL, and 0.02 ng/mL, respectively[1].
Cetrelimab binds to PD-1 in cynomolgus with a Kdvalue of 0.9 nM[1].

体内研究
(In Vivo)

Cetrelimab (10 mg/kg; i.p.; single dose) has antitumor efficacy, and decreases tumor volume in PD-1 knock-in (hPD-1KI) mice with MC38 tumor[1].
Cetrelimab (10 mg/kg; i.p.; once every 5 days for 30 d) results significant increases in peripheral blood CD8+T cells in patient-derived xenograft (PDX) lung model in mice[1].
Cetrelimab (10-100 mg/kg; i.v.; once weekly for 5 weeks) has well tolerance in cynomolgus model[1].
Cetrelimab (0.1-10 mg/kg; i.v.; single dose, monitored for 57 d) shows an nonlinear pharmacokinetics (PK) in cynomolgus, possibly attributable to target-mediated drug deposition (TMDD)[1].

Animal Model:hPD-1KI model with mouse PD-1 ECD replaced by the human PD-1 ECD[1]
Dosage:10 mg/kg
Administration:Intraperitoneal injection; single dose at day 7 after tumor implantation
Result:hPD-1KI mice develop normally and have no immune abnormalities.
Significantly lowered tumor volume at Day 21.
Animal Model:Patient-derived xenograft (PDX) LG1306 lung model in mice[1]
Dosage:10 mg/kg
Administration:Intraperitoneal injection; every 5 days for 6 cycles
Result:Significantly reduced patient-derived tumor volume by 32%.
Animal Model:Good Laboratory Practice (GLP) toxicity study in cynomolgus[1]
Dosage:0, 10, 30, or 100 mg/kg
Administration:Intravenous injection; once weekly for 5 weeks
Result:Showed well tolerance in cynomolgus.
CAS 号

2050478-92-5

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.